Drucker Wealth 3.0 LLC Has $817,000 Stock Holdings in Pfizer Inc. $PFE

Drucker Wealth 3.0 LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 51.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,078 shares of the biopharmaceutical company’s stock after selling 30,539 shares during the quarter. Drucker Wealth 3.0 LLC’s holdings in Pfizer were worth $817,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Horizon Financial Services LLC lifted its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new position in Pfizer in the fourth quarter valued at about $26,000. YANKCOM Partnership acquired a new position in Pfizer during the fourth quarter worth about $28,000. HFM Investment Advisors LLC raised its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Abound Financial LLC bought a new position in shares of Pfizer in the fourth quarter worth about $31,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer and Innovent’s GLP-1 drugs reportedly cleared a preliminary China insurance review, which could improve the commercial outlook for Ecnoglutide if it is eventually added to the country’s basic medical insurance catalogue. Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
• Positive Sentiment: Investor commentary continues to frame Pfizer as a value and dividend stock, with bullish arguments pointing to its lower forward valuation and income appeal, which may be helping sentiment around the shares. Is Pfizer Inc. (PFE) A Good Stock To Buy Now?
• Positive Sentiment: Pfizer is also being highlighted as one of several reliable dividend names in a volatile market, reinforcing the stock’s defensive-income profile for investors. 3 No-Brainer Dividend Stocks to Buy Right Now
• Neutral Sentiment: Pfizer signed a SuperHuman platform license agreement with Distributed Bio, which is a strategic R&D move but not yet a clear near-term earnings driver. Wired News – Pfizer Signs SuperHuman Platform License Agreement with Distributed Bio
• Negative Sentiment: Recent coverage also continues to weigh on sentiment, noting a CFO departure and a late-stage clinical miss in Pfizer’s oncology pipeline, which reinforces concerns about execution and growth prospects. Read More.

Pfizer Price Performance

PFE stock opened at $24.39 on Tuesday. The firm has a market cap of $139.04 billion, a price-to-earnings ratio of 18.62 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company’s fifty day simple moving average is $25.88 and its 200 day simple moving average is $26.28.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the previous year, the company posted $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on PFE shares. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Guggenheim increased their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. HSBC raised their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. Finally, Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.